INTRODUCTION

Guidelines and expert consensuses are documents that aim to help doctors evaluate the benefits and risks of diagnostic and therapeutic procedures related to a specific pathology. These documents are not intended to replace medical criteria and autonomy but to be useful guides for clinical decision-making. This guide was the result of a consensus of 20 experts from several medical specialties.

Each group of specialists conducted an exhaustive search of the available evidence in the current medical literature in PubMed and LILACS, the most frequently used search databases. A review of the literature regarding clinical manifestations and tools for diagnosis of LAL-D was conducted and the nominal group technique was followed. Results: Diagnostic algorithms which facilitate suspicion and diagnosis of LAL-D were generated by consensus for each of the risk groups. Conclusions: This guide proposes algorithms for the diagnosis of LAL-D based on clinical consensus. The algorithms seek to optimize diagnosis for patients with this pathology.

Keywords
Acid lipase deficiency, cholesterol ester deposition disease, Wolman's disease, dyslipidemia, hepatomegaly.
This guide was developed by a committee of experts in pediatrics, pediatric gastroenterology, pediatric endocrinology, hepatology, pathology and genetics using nominal group technique (NGT). Based on their experience and a wide literature review, the experts debated and discussed their different points of view to arrive at a list of recommendations representing their collective judgment. The objective was to propose guidelines that can be used in clinical practice for identification of patients with this pathology in Colombia.

PHYSIOPATHOLOGY

LAL-D originates in mutations of the LIPA gene located at 10q23.2. It has 10 exons and an approximate length of 45 kilobases (kb). (1) This entity is autosomal recessive inheritance whose most common defect is associated with a mutation at the site of exon 8 (c.894G> A) which is known as E8SJM. This mutation is present in about half of the affected patients, (12) To date, more than 40 mutations which lead to alterations of the enzyme’s function and which are related to this pathology have been described. (2) The most drastic ones are nonsense and frameshift mutations which are usually associated with severely affected patients, while cases in children and adults are associated with mutations whose effects on the protein are not so dramatic. (13)

The LAL enzyme plays a key role in the metabolism of lipids since it is responsible for hydrolysis of cholesterol esters and triglycerides within lysosomes. (14) The action of this enzyme generates free cholesterol which is involved in negative regulation of LDL receptors, in the inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase which is a rate controlling enzyme, and in the stimulation of acyl-coenzyme A (CoA):cholesterol acyltransferase (ACAT). Congenital deficiencies of this enzyme lead to lysosomal accumulation of cholesterol and triglyceride esters and to failure of the LDL receptor pathway. Therefore, in addition to this massive lysosomal accumulation of cholesterol esters, there is a systemic increase in synthesis of cholesterol. (15)

CLINICAL PICTURE

Acid lipase deficiencies have a wide range of phenotypic presentations which manifest in very early childhood, in later childhood or in later stages of life.

Presentation in Infants

LAL-D usually manifests with the most acute symptoms when it manifests in the first days of life. Gastrointestinal symptoms include vomiting, diarrhea, steatorrhea, and
abdominal distension secondary to hepatosplenomegaly. In addition, infants fail to thrive. (10) Increases of lipid deposits in the gastrointestinal tract cause thickening of the intestines resulting in malnutrition and malabsorption syndrome. (16) Calcification of the adrenal glands is characteristic of this pathology, is present in up to 78% of affected children, and can cause cortical adrenal insufficiency. (17) Patients progress to multiorgan failure, especially to liver failure with cirrhosis and cachexia, and this leads to early death: on average, at 3.7 months. (5)

Presentation in Children and Adults

Presentation can be similar to that in infants. One third of patients experience severe gastrointestinal symptoms including frequent diarrhea, vomiting, abdominal pain, malabsorption and steatorrhea. (2, 14) Cholestasis, growth failure and gallbladder dysfunction are also important symptoms. (2) Classically, patients develop dyslipidemia and their total cholesterol increases as LDL and apolipoprotein B levels become elevated while HDL levels fall. (2, 14) This hyperlipidemia is associated with atherosclerosis, coronary artery disease and early catastrophic vascular events. (2, 18) Occasionally cholesterol deposits may be visible as xanthelasma develops (particularly in the palpebral region). (19) Hepatomegaly with or without splenomegaly is common and is present in 99% of children and 74% of adults with LAL-D. (2) Usually, organomegaly may be the first finding and is present many years before the diagnosis is made. (20) Patients with splenomegaly may develop anemia or thrombocytopenia secondary to hypersplenism.

Liver involvement is common and elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may be early signs of liver damage. This can manifest with or without jaundice, steatosis, fibrosis or cirrhosis. Liver damage can lead to esophageal varices and progress to liver failure, cirrhosis, or hepatocellular carcinoma. (21) Lipid deposits in the intestines can lead to diarrhea and weight loss. (22)

DIAGNOSIS

LAL-D can be diagnosed by measuring the activity of the acid lipase enzyme or by determining mutations in the LIPA gene. (14)

- Measurement of LAL activity is done with dried blood spot testing (DBS) using a fluorometric substrate of 4-methylumbelliferyl palmitate (4 mU palmitate). (23) Because the presence of other lipases in the blood can interfere with measurement, Lalistat 2 (Chemical Tools, South Bend, IN, USA), a LAL inhibitor, is used. (23) The activity of LAL is determined by comparing total lipase activity with lipase activity in the presence of the inhibitor. The difference between the two can be attributed to the LAL enzyme. This measurement can be performed with leukocytes and with DBS, both of which have similar values for sensitivity and specificity. (24) Nevertheless, measurement with DBS has had excellent results in discriminating between healthy and affected patients with intermediate values for carriers. It also has the advantages of being easy to take and transport and is very stable in the long term. (23, 24)

- Molecular study through complete sequencing of the coding region of the LIPA gene allows identification of the causative mutations of the disease. The majority of patients are homozygous or have compound heterozygotes. However, some patients may have intrinsic mutations that are not always detected by sequencing. (14) For this reason, the method of choice for diagnosis is measurement of enzymatic activity while molecular tests are considered to be complementary.

Figure 1 summarizes the algorithm for diagnosis of LAL-D. Other tests can be used when there is suspicion of this pathology, but they do not confirm the diagnosis.

Typically, liver biopsies will show microvesicular or mixed steatosis, but these conditions are not exclusive to LAL-D. Other findings including the presence of sea-blue histiocytes, increased size of Kupffer cells with enlarged vacuoles, lipid drops and cholesterol crystals can support the diagnosis. (9) Immunohistochemistry testing for cathepsin D and lysosomal-associated membrane proteins 1 and 2 (LAMP1 and LAMP2), which are all lysosomal markers, can also be used. (25)

DEFINITION OF RISK GROUPS

Because the clinical picture of LAL-D is similar to those of other cardiovascular, liver and metabolic diseases, it is possible to make inappropriate diagnoses that delay appropriate management of these patients.

Taking this into account, it was decided to establish an algorithm for each risk group to allow establishment of the appropriate stage of the diagnostic process for performing the LAL enzyme activity test. The theoretical framework and the diagnostic routes that have been developed are presented below.

Liver Diseases

Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) requires imaging or histological evidence of hepatic steatosis, and elimination of other possible causes for accumulation of liver fat such as alcohol consumption, the use of steatogenic
medications and hereditary disorders. In most cases it is associated with metabolic risk factors such as obesity, diabetes mellitus (DM) and dyslipidemia. One special type of NAFLD is non-alcoholic steatohepatitis (NASH). NAFLD is defined as the presence of hepatic steatosis without evidence of hepatocellular damage. NASH is described as the presence of hepatic steatosis, inflammation, and damage to hepatocytes with or without fibrosis. (26)

Common causes of hepatic steatosis include significant alcohol consumption, hepatitis C, cystic fibrosis, medications, parenteral nutrition, autoimmune hepatitis, severe malnutrition and medications including ethanol, corticosteroids, and estrogens. These should be considered and ruled out in the initial study of the patient, and a complete viral/imunological profile should be made to exclude the most common disorders.

LAL-D should be suspected in patients with NASH or NAFLD who have the following signs and symptoms:
- Persistently elevated transaminases despite weight loss.
- Dyslipidemia indicated by increased LDL values and decreased HDL according to age which does not improve after changes in lifestyle or medication.
- Rapid progression of disease.

Figure 2 shows the algorithm for diagnosis of LAL-D in patients with fatty liver disease.

**Hepatomegaly**

Normal liver size is based on values established by percussion, of extension below the right costal margin, or by the length of the vertical axis estimated by imaging studies. In general, it is estimated that measurements over 3.5 cm in neonates and 2 cm in children obtained by palpation under the right costal margin on the mid-clavicle line indicate hepatomegaly. (27)

Hepatomegaly can be caused by five different mechanisms: inflammation, excessive deposition, infiltration, congestion and obstruction.

1. Inflammation is usually secondary to infections, toxins, radiation, autoimmune diseases and/or Kupffer cell hyperplasia that lead to inflammatory-type hepatomegaly.
2. Deposits are mainly glycogen, lipids, fat, metals and abnormal proteins.
3. Infiltration develops in cases of tumors, parasitic cysts and extramedullary hematopoiesis.
4. Vascular congestion is due to obstruction of venous drainage between the liver and the right atrium and may be intrahepatic or extrahepatic.
5. Biliary obstruction occurs in biliary atresia, choledochal cysts, cholelithiasis and tumors of the liver, bile duct, pancreas and duodenum. (27)

A clinical history, physical examination, and complementary tests including a complete blood count, coagulation test, liver function tests, blood gas analysis, urinary sediment test and ultrasound are necessary for pediatric patients with hepatomegaly allow selection of other complementary tests to be performed.

Figures 3 and 4 show diagnostic algorithms for transaminases.

---

**Figure 1.** Algorithm for diagnosis of LAL-D.
Gaucher disease is an autosomal recessive disorder caused by deficiency of glucocerebrosidase (GCase), a lysosomal hydrolase. Its estimated incidence is 1:200,000. The disease should be suspected when histopathology of biopsies from the bone marrow, liver and/or spleen reveal Gaucher cells, but measurement of GCase activity in leukocytes or fibroblasts obtained from a skin biopsy is the gold standard for diagnosis. (28) A molecular study of the GBA gene can be carried out for confirmation.

Clinically, this disease affects a number of systems, so its phenotypes are divided into non-neuronopathic and neuronopathic. Clinical manifestations of non-neuronopathic Gaucher disease vary greatly, but most are hematological including anemia and thrombocytopenia, visceral including hepatosplenomegaly, or compromise bones. Secondary neurological complications may occur as a result of nerve compression of the spinal cord due to vertebral collapse. (28-30)

**Acid Sphingomyelinase Deficiency (Niemann-Pick Disease A and B)**

Acid sphingomyelinase (ASM) deficiency is an autosomal recessive disorder caused when enzymatic activity of ASM is less than 10% of control sample activity or by the presence of pathogenic biallelic mutations in the SMPD1 gene (also called the ASM gene). (31, 32)

Classically, this disorder has been divided into neuronopathic (Niemann-Pick A disease) or non-neuronopathic

---

**METABOLIC HEPATOPATHIES**

**Gaucher Disease**

Gaucher disease is an autosomal recessive disorder caused by deficiency of glucocerebrosidase (GCase), a lysosomal hydrolase. Its estimated incidence is 1:200,000.

The disease should be suspected when histopathology of biopsies from the bone marrow, liver and/or spleen reveal Gaucher cells, but measurement of GCase activity in leukocytes or fibroblasts obtained from a skin biopsy is the gold standard for diagnosis. (28) A molecular study of the GBA gene can be carried out for confirmation.

Clinically, this disease affects a number of systems, so its phenotypes are divided into non-neuronopathic and neuronopathic. Clinical manifestations of non-neuronopathic Gaucher disease vary greatly, but most are hematological including anemia and thrombocytopenia, visceral including hepatosplenomegaly, or compromise bones. Secondary neurological complications may occur as a result of nerve compression of the spinal cord due to vertebral collapse. (28-30)
Figure 3. Algorithm for the suspicion of LAL-D in the presence of elevated transaminases. * Pediatric: LDL (mg/dL) ≥ 130 or HDL (mg/dL) ≤ 45; Adult: LDL (mg/dL) ≥ 160 or HDL (mg/dL) ≤ 40 (men)/≤ 50 (women). Ac: antibodies; Anti-HCV: hepatitis C virus antibodies; HBV: hepatitis B virus

Figure 4. Algorithm for the suspicion of LAL-D after finding hepatomegaly. * Pediatric: LDL (mg/dL) ≥ 130 or HDL (mg/dL) ≤ 45; Adult: LDL (mg/dL) ≥ 160 or HDL (mg/dL) ≤ 40 (men)/≤ 50 (women). Ac: antibodies; Anti-HCV: hepatitis C virus antibodies; HBV: hepatitis B virus
According to the International Diabetes Federation, the criteria for this syndrome have been defined as the presence of at least three of the following five factors:

1. Large waist size according to the criteria of the country and the specific population.
2. Triglycerides over 150 mg/dL.
3. Low HDL cholesterol (<40 mg/dL in men and <50 mg/dL in women).
4. High in blood pressure (systolic pressure ≥130 mm Hg or diastolic pressure ≥85 mm Hg).
5. High fasting glucose (blood glucose >100 mg/dL).

Numerous contributing factors have been described for development of metabolic syndrome. They include genetic factors, lifestyle factors such as diet and physical activity, obesity and insulin resistance. All are important for pathogenesis of metabolic syndrome, but insulin resistance is a key factor that connects and contributes to the development of the disorder. (38)

Table 1 summarizes the differences between LAL-D and metabolic syndrome.

The expert consensus for diagnosis of patients who have signs and symptoms of metabolic syndrome is summarized in Figure 6.

DYSLIPIDEMIAS

Familial Hypercholesterolemia

Familial Hypercholesterolemia is a disease based on an autosomal dominant inheritance that leads to severe elevation of total cholesterol and LDL. There are homozygous and in heterozygous forms of presentation.

Homozygous patients present symptoms consistent with peripheral vascular disease, ischemic heart disease, cerebrovascular disease or aortic stenosis. They may also develop joint symptoms such as tenosynovitis and arthralgia, and at birth. At birth and in early childhood there may be cutaneous xanthomas. (39) Most homozygous patients who do not receive treatment die before 30 years of age.

Heterozygous patients are usually asymptomatic, but they may have histories of severe hypercholesterolemia from childhood and may later develop xanthelasmas or xanthomas. (39)

The fundamental finding for diagnosis of both homozygous and heterozygous forms is the cholesterol level in the absence of secondary causes of hypercholesterolemia. Nevertheless, the definitive diagnosis can only be made with molecular confirmation through analysis of the LDLR, APOB, or PCSK9 genes. (40)
Familial Combined Hyperlipidemia

Familial combined hyperlipidemia is the most frequent inherited lipid metabolism disorder that is associated with mixed hyperlipidemia and premature cardiovascular disease. Although symptoms may appear in childhood, it usually manifests in the second decade of life with hyper-
cholesterolemia or hypertriglyceridemia. It is frequently associated with numerous metabolic abnormalities such as hypertension, insulin resistance, DM2, central obesity, hepatic steatosis and metabolic syndrome. (42)

It is characterized by an autosomal dominant inheritance with high penetrance and oligogenic etiology.

The following criteria should be taken into account for diagnosis:

1. Affected person
   - In adults: total cholesterol > 240 mg/dl (or c-LDL> 160 mg/dL) and/or triglycerides > 200 mg/dL.
   - In children under 20 years of age: total cholesterol > 200 mg/dL (or c-LDL > 130 mg/dL) or triglycerides > 120 mg/dL.
   - Discard secondary causes: body mass index (BMI) > 35 kg/m2, glycosylated hemoglobin (HbA1c) > 10%, uncontrolled hypothyroidism or alcoholism (more than 40 g alcohol/day).

2. Affected family
   - Two or more first-degree members (parents, siblings or children) affected by mixed hyperlipidemia or combinations of pure hypercholesterolemia (IIa), mixed hyperlipidemia (IIb) and hypertriglyceridemia (IV).
   - Families with tendinous xanthomas or LDL-c levels > 300 mg/dL in two or more first-degree relatives with phenotype IIa are excluded.
   - Family history of premature atherosclerotic cardiovascular disease (prior to sixty years of age) (42).

CONCLUSION

LAL-D’s prevalence is small, but this may be due to large amounts of under diagnosis and misdiagnosis. These guidelines aim at defining which patients should be tested for this disease, so that these patients will receive timely and effective treatment to change their prognoses and quality of life.

These guidelines for developing diagnostic suspicion are a reference for the clinical practices of general practitioners and specialists.

REFERENCES

18. Elleder M, Chlumská A, Hyánek J, et al. Subclinical course of cholesteryl ester storage disease in an adult with hyper-


